½ÃÀ庸°í¼­
»óǰÄÚµå
1753974

½º¸¶Æ® ½Ã¸°Áö ½ÃÀå º¸°í¼­ : Á¦Ç°º°, ¿¬·ÉÃþº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Smart Syringe Market Report by Product, Age Group, Application, End User (Hospitals and HMOs, Diabetic Patients, Family Practices, Psychiatrics, and Others), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 136 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 102¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 181¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 6.30%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¾ÈÀü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»óÀ» ¿¹¹æÇÒ Çʿ伺 Áõ°¡, ¾ÈÀüÇÑ ÁÖ»ç ¹æ¹ý¿¡ ´ëÇÑ ±ÔÁ¦ °­È­, ÀÇ·á ±â¼ú ¹ßÀü, ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ Áõ°¡, HIV ¹× °£¿°°ú °°Àº °¨¿°¼º ÁúȯÀÇ È®»êÀ» ¾ïÁ¦Çϱâ À§ÇÑ Àü ¼¼°èÀûÀÎ ³ë·Â µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

½º¸¶Æ® ½Ã¸°Áö´Â Àç»ç¿ëÀ» ¹æÁöÇÏ°í ¾ÈÀüÇÏÁö ¾ÊÀº Áֻ縦 ±ÔÁ¦Çϱâ À§ÇÑ ¾ÈÀü ¸ÞÄ¿´ÏÁòÀ» °®Ãá ÀÇ·á±â±âÀÔ´Ï´Ù. »çÀü ¼³Á¤µÈ ¸Å°³º¯¼ö, »ç¿ë ¹üÀ§, »ç¿ë »óȲ ÃßÀû ±â´ÉÀ» °®Ãá Àбâ/¾²±â °¡´ÉÇÑ Ä¨ÀÌ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î ÀÚµ¿ ºñȰ¼ºÈ­(AD), ÆÐ½Ãºê ¼¼ÀÌÇÁƼ, ¾×Ƽºê ¼¼ÀÌÇÁƼ ÁÖ»ç±â µî ´Ù¾çÇÑ Á¾·ù°¡ ÀÖ½À´Ï´Ù. Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV), AÇü °£¿°, BÇü °£¿°, ´ç´¢º´°ú °°Àº ½É°¢ÇÑ Áúº´À̳ª Áõ»óÀ» °¡Áø ȯÀÚÀÇ Ä¡·á¿¡ µµ¿òÀÌ µË´Ï´Ù. ¹é½Å Á¢Á¾, ¾à¹°Àü´Þ, Ç÷¾× °Ëü äÃë µî¿¡ »ç¿ëµË´Ï´Ù. ±× °á°ú, Àü ¼¼°è º´¿ø, Áø·á¼Ò, Áø´Ü¼Ò, ¿¹¹æÁ¢Á¾¼¾ÅÍ¿¡¼­ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

½º¸¶Æ® ½Ã¸°Áö ½ÃÀå µ¿Çâ:

°¨¿° ¿¹¹æ°ú ÀÇ·á ¾ÈÀü¿¡ ´ëÇÑ Á߿伺 Áõ°¡

ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â Áúº´ °¨¿°À» ¿¹¹æÇϱâ À§ÇØ ¾ÈÀüÇÑ Áֻ縦 ½ÃÇàÇÏ´Â °ÍÀ» ¿ì¼±½ÃÇϱ⠶§¹®¿¡ °¨¿° ¿¹¹æ¿¡ ´ëÇÑ °ü½ÉÀÌ ½º¸¶Æ® ½Ã¸°Áö ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±âÁ¸ ÁÖ»ç±â´Â ÀϺΠÁö¿ª¿¡¼­´Â ÀÚ¿øÀÇ Á¦¾àÀ¸·Î ÀÎÇØ Àç»ç¿ëµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ´Â HIV, °£¿°°ú °°Àº °¨¿°¼º ÁúȯÀ» È®»ê½Ãų ¼ö ÀÖ´Â À§ÇèÀ» Å©°Ô Áõ°¡½Ãŵ´Ï´Ù. ÀÚµ¿ ºñȰ¼ºÈ­ ±â´É°ú ¾ÈÀü Àá±Ý ±â´ÉÀ» °®Ãá ½º¸¶Æ® ½Ã¸°Áö´Â Àç»ç¿ëÀ» ¹æÁöÇϵµ·Ï ¼³°èµÇ¾î ÀÌ·¯ÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ±¹°¡¿¡¼­ ÀÇ·á¿ë ¾ÈÀü ÁÖ»ç±â »ç¿ëÀ» Àǹ«È­Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è °¨¿° °ü¸®¸¦ ¿ËÈ£ÇÏ´Â º¸°Ç ´ÜüÀÇ ±Ç°í¿¡ µû¸¥ °ÍÀÔ´Ï´Ù. ÀÇ·á °ü·Ã °¨¿°¿¡ ´ëÇÑ Àνİú ±ÔÁ¦°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ½Ã¼³°ú Á¶Á÷Àº ½º¸¶Æ® ½Ã¸°Áö¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ½Ã¸°Áö ½ÃÀå ºÐ¼®¿¡ µû¸£¸é, ÀÌ·¯ÇÑ º¯È­´Â º´¿ø, Áø·á¼Ò, ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖÀ¸¸ç, °¨¿° ¿¹¹æ Á¶Ä¡´Â ÀÇ·áÁø°ú ȯÀÚ ¸ðµÎ¸¦ ÀáÀçÀû °¨¿° ¿äÀο¡ ³ëÃâµÇÁö ¾Êµµ·Ï º¸È£ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

ÀÇ·á±â¼úÀÇ ¹ßÀü°ú ÀÏȸ¿ë ÀÇ·á±â±â

ÀÇ·á ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀº ½º¸¶Æ® ½Ã¸°Áö ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ÀÏȸ¿ë ¾ÈÀü ¼³°è ±â±â°¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó, ½º¸¶Æ® ½Ã¸°Áö¿¡ ´ëÇÑ ¿¬±¸°³¹ß(R&D) ÅõÀÚ´Â ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»óÀ» ÃÖ¼ÒÈ­Çϰí Àç»ç¿ëÀ» ¹æÁöÇϵµ·Ï ¼³°èµÈ Á¢ÀÌ½Ä ¹Ù´Ã°ú ÀÚµ¿ ºñȰ¼ºÈ­ ¸ÞÄ¿´ÏÁò°ú °°Àº °í±Þ ±â´ÉÀÇ °³¹ß·Î À̾îÁ® Àüü ½º¸¶Æ® ½Ã¸°Áö ½ÃÀåÀÇ Á¡À¯À²À» ´õ¿í È®´ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÁÖ»ç±âÀÇ ¾ÈÀü¼º°ú ±â´É¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ÁÖ»ç±âÀÇ Á¢±Ù¼ºÀ» ³ôÀÌ°í °¡°ÝÀ» ³·Ãß´Â µ¥¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Àü ¼¼°è ±ÔÁ¦ ±â°üµéÀº ´õ¿í ¾ö°ÝÇÑ ¾ÈÀü °¡À̵å¶óÀÎÀ» ¼³Á¤ÇÏ¿© Á¦Á¶¾÷üµéÀÌ ´õ ¸¹Àº Çõ½ÅÀ» Çϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ±³Â÷ ¿À¿°ÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ´Â ÀÏȸ¿ë ÀÇ·á±â±â·ÎÀÇ ÀÇ·á »ê¾÷ÀÇ Àüȯ°ú ÀÏÄ¡ÇÕ´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ½º¸¶Æ® ½Ã¸°Áö´Â ƯÈ÷ º´¿øÀ̳ª Áø·á¼Ò¿Í °°Àº °íÀ§Çè ȯ°æ¿¡¼­ º¸´Ù ¾ÈÀüÇÑ Áø·á¸¦ Áö¿øÇÏ°í °¨¿° °¡´É¼ºÀ» ³·Ãß±â À§ÇØ Çö´ë ÀÇ·á ½Ã¼³¿¡ ¾ø¾î¼­´Â ¾È µÉ ÇʼöǰÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ È®´ë ¹× ¼¼°è ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ³ë·Â

Àü ¼¼°èÀÇ ¿¹¹æÁ¢Á¾ ³ë·ÂÀÌ ½º¸¶Æ® ½Ã¸°Áö¿¡ ´ëÇÑ ¼ö¿ä¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷, ÃÖ±Ù ¼¼°è º¸°Ç ¹®Á¦¸¦ °í·ÁÇÒ ¶§ ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ½º¸¶Æ® ½Ã¸°Áö ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¾ÈÀü ¼³°è ÁÖ»ç±â »ç¿ëÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ½Ã¸°Áö, ƯÈ÷ ÀÚµ¿ ºñȰ¼ºÈ­ ÁÖ»ç±â´Â ÀÏȸ¿ëÀ̱⠶§¹®¿¡ ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ ¿­¾ÇÇÑ Áö¿ª¿¡¼­ Áý´Ü ¿¹¹æÁ¢Á¾¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·Î±×·¥µéÀº ¿¹¹æ °¡´ÉÇÑ Áúº´ÀÇ È®»êÀ» ¾ïÁ¦ÇÏ´Â µ¥ ÀÖ¾î ¾ÈÀüÇÑ ÁÖ»ç ½ÇõÀÌ Áß¿äÇÏ´Ù´Â Á¡À» °­Á¶Çϸç, ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ½º¸¶Æ® ½Ã¸°Áö ½ÃÀå ¿¹Ãø¿¡ µû¸£¸é, ¿¹¹æÁ¢Á¾ ¹üÀ§¸¦ È®´ëÇÏ°í ¾ÈÀüÇÑ Åõ¿©¸¦ º¸ÀåÇϱâ À§ÇØ ³ë·ÂÇÏ´Â ±¹°¡°¡ ´Ã¾î³²¿¡ µû¶ó ½º¸¶Æ® ½Ã¸°ÁöÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ¿© ¾ÈÀü ÇÁ·ÎÅäÄÝÀ» ÁؼöÇϸ鼭 ¹é½ÅÀ¸·Î ¿¹¹æ °¡´ÉÇÑ Áúº´ÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2024³â ¼¼°è ½º¸¶Æ® ½Ã¸°Áö ½ÃÀå ±Ô¸ð´Â?
  • 2025-2033³â ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀå ¼ºÀå·ü Àü¸ÁÀº?
  • ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • COVID-19°¡ ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¦Ç°º° ºÐ·ù´Â ¾î¶»°Ô µÇ´Â°¡?
  • ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀå¿¡¼­ÀÇ ¿¬·É´ëº° ºÐ·ù´Â ¾î¶»°Ô µÇ´Â°¡?
  • ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀå¿¡¼­ÀÇ ¿ëµµº° ºÐ·ù´Â?
  • ¼¼°è ½º¸¶Æ® ½Ã¸°Áö ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ÇöȲÀº?
  • ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ½º¸¶Æ® ½Ã¸°Áö ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä Ç÷¹À̾î/±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ½º¸¶Æ® ½Ã¸°Áö ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ÀÚµ¿ ºñȰ¼ºÈ­ ÁÖ»ç±â
  • ¾×Ƽºê ¾ÈÀü ÁÖ»ç±â
  • ÆÐ½Ãºê ¾ÈÀü ÁÖ»ç±â

Á¦7Àå ½ÃÀå ³»¿ª : ¿¬·ÉÃþº°

  • ¼Ò¾Æ
  • ¼ºÀÎ

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ¾à¹°Àü´Þ
  • ¹é½Å Á¢Á¾
  • Ç÷¾× °Ëü äÃë

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø¡¤HMO
  • ´ç´¢º´ ȯÀÚ
  • °¡Á¤ÀÇ·á(ÀÇ»ç)
  • Á¤½Å ÀÇ·á
  • ±âŸ

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • AdvaCare Pharma
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company
    • Gerresheimer AG
    • Merit Medical Systems Inc.
    • Nipro Corporation
    • Numedico Technologies Pty Ltd.
    • Retractable Technologies Inc.
    • Terumo Corporation
ksm

The global smart syringe market size reached USD 10.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.1 Billion by 2033, exhibiting a growth rate (CAGR) of 6.30% during 2025-2033. The increasing awareness of healthcare safety, the rising need to prevent needle-stick injuries, growing regulations on safe injection practices, advancements in healthcare technologies, rising vaccination programs, and the global focus on reducing the spread of infections, such as HIV and hepatitis are some of the major factors propelling the market growth.

A smart syringe is a medical device engineered with safety mechanisms to prevent reuse and regulate unsafe injection practices. It is incorporated with a read and write chip with preset parameters, ranges, and usage tracking. It is commonly available in variants of auto-disable (AD), passive safety, and active safety syringes. It aids in treating patients with critical disorders and conditions, such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and diabetes. It is used for vaccination, drug delivery, and blood specimen collection. As a result, it is utilized in hospitals, clinics, diagnostics, and vaccination centers across the globe.

Smart Syringe Market Trends:

Growing Emphasis on Infection Prevention and Healthcare Safety

The focus on infection control is a major driver in the smart syringe market as healthcare providers prioritize safe injection practices to prevent disease transmission. Traditional syringes, often reused in some regions due to resource constraints, significantly raise the risk of spreading infections like HIV and hepatitis. Smart syringes, equipped with auto-disable and safety lock features, are designed to eliminate reuse, addressing these concerns effectively. Many countries now mandate the use of safety syringes in healthcare, aligning with recommendations from health organizations that advocate for global infection control. The increasing awareness and regulations related to healthcare-associated infections encourage healthcare facilities and organizations to adopt smart syringes. According to the smart syringe market analysis, this shift is evident in hospitals, clinics, and vaccination programs, where infection prevention measures are critical to protecting both healthcare workers and patients from potential exposure to infectious agents.

Advancements in Medical Technology and Disposable Healthcare Devices

Ongoing innovations in medical technology significantly drive the smart syringe market growth, especially as healthcare systems increasingly prefer disposable, safety-engineered devices. In line with this, research and development (R&D) investments in smart syringes have led to the development of advanced features such as retractable needles and auto-disable mechanisms, designed to minimize needle-stick injuries and prevent reuse, which is further expected to increase the overall smart syringe market share. These innovations are not only enhancing the safety and functionality of syringes but are also making them more accessible and affordable. In addition to this, regulatory bodies worldwide are setting stricter safety guidelines, prompting manufacturers to innovate further. This technological evolution aligns with the healthcare industry's shift towards single-use medical devices, which help mitigate cross-contamination risks. As technology improves, smart syringes are becoming integral to modern healthcare facilities, supporting safer practices and reducing the chances of infection, particularly in high-risk environments such as hospitals and clinics.

Expansion of Immunization Programs and Global Vaccination Efforts

Worldwide immunization initiatives are accelerating the demand for smart syringes, particularly with large-scale vaccination programs becoming increasingly critical considering recent global health challenges, which are boosting the smart syringe market growth across the globe. Organizations such as WHO and UNICEF have underscored the importance of using safety-engineered syringes in these campaigns to prevent needle reuse and reduce the risk of cross-contamination. Smart syringes, particularly auto-disable types, ensure single-use applications, making them ideal for mass immunization drives, especially in regions with limited healthcare infrastructure. These programs underscore the importance of safe injection practices in controlling the spread of preventable diseases which is expected to drive the market growth. According to the smart syringe market forecast, as more countries commit to expanding immunization coverage and ensuring safe administration, the adoption of smart syringes is expected to rise, helping reduce the burden of vaccine-preventable diseases while ensuring adherence to safety protocols.

Key Market Segmentation:

Breakup by Product:

  • Auto-disable Syringes
  • Active Safety Syringes
  • Passive Safety Syringes

Breakup by Age Group:

  • Pediatrics
  • Adults

Breakup by Application:

  • Drug Delivery
  • Vaccination
  • Blood Specimen Collection

Breakup by End User:

  • Hospitals and HMOs
  • Diabetic Patients
  • Family Practices (Physicians)
  • Psychiatrics
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global smart syringe market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

  • AdvaCare Pharma
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Gerresheimer AG
  • Merit Medical Systems Inc.
  • Nipro Corporation
  • Numedico Technologies Pty Ltd.
  • Retractable Technologies Inc.
  • Terumo Corporation

Key Questions Answered in This Report

  • 1.What was the size of the global smart syringe market in 2024?
  • 2.What is the expected growth rate of the global smart syringe market during 2025-2033?
  • 3.What are the key factors driving the global smart syringe market?
  • 4.What has been the impact of COVID-19 on the global smart syringe market?
  • 5.What is the breakup of the global smart syringe market based on the product?
  • 6.What is the breakup of the global smart syringe market based on age group?
  • 7.What is the breakup of the global smart syringe market based on the application?
  • 8.What is the breakup of the global smart syringe market based on the end user?
  • 9.What are the key regions in the global smart syringe market?
  • 10.Who are the key players/companies in the global smart syringe market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Smart Syringe Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Auto-disable Syringes
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Active Safety Syringes
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Passive Safety Syringes
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Age Group

  • 7.1 Pediatrics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adults
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Drug Delivery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Vaccination
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Blood Specimen Collection
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and HMOs
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diabetic Patients
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Family Practices (Physicians)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Psychiatrics
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AdvaCare Pharma
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 B. Braun Melsungen AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Becton, Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Gerresheimer AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Merit Medical Systems Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Nipro Corporation
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Numedico Technologies Pty Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Retractable Technologies Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Terumo Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦